Efficacy of aspirin for secondary prevention in patients with peripheral artery disease

Dmitriy N. Feldman, Issam D. Moussa

Research output: Contribution to journalComment/debatepeer-review

Abstract

Aspirin decreases the risk of cardiovascular events in patients with prior coronary heart or cerebrovascular disease. The American College of Cardiology/American Heart Association guidelines recommend a low-dose aspirin regimen (75-325 mg/day) to reduce the risk of cardiovascular events in patients with peripheral artery disease (PAD). However, the effect of aspirin for secondary prevention in patients with PAD has not been well established. The paper under evaluation performed a meta-ana lysis of 18 trials to investigate the effect of aspirin on cardiovascular events (nonfatal myocardial infarction, nonfatal stroke and cardiovascular death) in patients with PAD. The results of this meta-ana lysis in a PAD cohort revealed that treatment with aspirin did not significantly reduce the combined end point of cardiovascular events; however, aspirin resulted in a significant reduction in the incidence of nonfatal stroke. This analysis raises a number of questions regarding the overall efficacy of aspirin in PAD and what should be the optimal antiplatelet therapy in patients with PAD: aspirin, clopidogrel or perhaps a combination of aspirin and clopidogrel.

Original languageEnglish (US)
Pages (from-to)1203-1207
Number of pages5
JournalExpert Review of Cardiovascular Therapy
Volume7
Issue number10
DOIs
StatePublished - Oct 2009
Externally publishedYes

Keywords

  • Aspirin
  • Claudication
  • Peripheral artery disease
  • Peripheral vascular disease

ASJC Scopus subject areas

  • Internal Medicine
  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of 'Efficacy of aspirin for secondary prevention in patients with peripheral artery disease'. Together they form a unique fingerprint.

Cite this